Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x100px
Document › Details

Lonza Group Ltd.. (3/23/22). "Press Release: Christian Seufert Appointed as President of Capsules and Health Ingredients Division". Basel.

Organisations Organisation Lonza Group AG (SWX: LONN)
  Today Lonza (Group)
  Group Lonza (Group)
  Organisation 2 BASF S.E.
  Group BASF (Group)
Products Product oral drug delivery technology
  Product 2 contract manufacturing (drugs)
Persons Person Seufert, Christian (Lonza 202207– President of Capsules + Health Ingredients Div + Exec Board Member before 20y at BASF)
  Person 2 Ruffieux, Pierre-Alain (Lonza 202011– CEO before Roche + Novartis + Serono)

> Lonza appoints Christian Seufert as President of the CHI Division and member of the Executive Committee

> Christian brings a unique level of experience and expertise from a 20-year career at BASF across multiple territories and businesses

> He will commence his tenure with Lonza Group on 1 July 2022

> Christian succeeds Claude Dartiguelongue who retires from Lonza on 31 July 2022

Lonza today announced that its Board of Directors has appointed Christian Seufert as President of Capsules and Health Ingredients Division. The appointment will be effective from 1 July 2022. Christian will succeed Claude Dartiguelongue as a member of the Lonza Group Executive Committee.

Christian joins Lonza Group from BASF, where he has worked for the last 20 years. Most recently, he held the role of Senior Vice President for the Global Business Unit Pharma Solutions and represented the Nutrition & Health division in North and South America since 2018. In this role, Christian was responsible for driving organic growth with a focus on biologics and new digital business models. With his global team he delivered new product line strategies for selected APIs and pharmaceutical excipients, improved operational excellence, and managed business continuity through the COVID-19 pandemic.

Albert M. Baehny, Chairman, Lonza, commented: “We extend a warm welcome to Christian as he joins the Lonza Group Executive Committee. Christian will lead a thriving Division which delivers strong cash generation and shows high long-term potential. His knowledge and understanding of our business will help us to achieve further improvements in operational excellence while continuing our growth journey.”

Pierre-Alain Ruffieux, CEO, Lonza, added: “Christian is uniquely placed to lead our CHI business, with a wealth of experience and expertise in both our operations as well as the industry in which we operate. Christian joins our leadership team as we continue to consolidate our leading market position and maintain our focus on driving accelerated growth and long-term success.”

Prior to his most recent role in BASF, Christian held multiple roles with increasing levels of responsibility in BASF Group. Other roles have included Vice President of the global Aroma Ingredients business (2015 – 2018) and Vice President for the European Business Management Home Care, Industrial and Institutional Cleaning (2012 – 2014).

Christian holds a graduate degree in business administration and economics from the University of Hohenheim as well as Executive and post-graduate qualifications from INSEAD and IMD Business School (Lausanne, Switzerland). He is relocating from the US to live in Basel with his wife.

Christian will succeed Claude Dartiguelongue, who has been the President of the Capsules and Health Ingredients Division since January 2020. Claude has played a critical role in creating a clear organizational structure and performance culture in the CHI Division, as well as maintaining a focus on quality and speed. She has set the strategic direction of the Division, while enhancing the approach to customer-centricity and value creation. As part of her role on the Executive Committee, Claude has also played an instrumental role in strategic projects across the Group.

Claude will retire on 31 July 2022. She is a highly regarded member of the Lonza leadership and she will be greatly missed by her colleagues. The Lonza management would like to thank her for her many valuable contributions, and wish her a well-deserved happy retirement.

Notes to editors

A high-resolution image of Christian is available on request from

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to prevent illness and enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare industry.

Founded in 1897 in the Swiss Alps, today Lonza operates across five continents. With approximately 16,000 full-time employees, we comprise high-performing teams and of individual talent who make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. Find out more at

Follow @Lonza on LinkedIn
Follow @LonzaGroup on Twitter

Lonza Contact Details

Victoria Morgan
Head of ExternalCommunications
Lonza Group Ltd
Tel +41 61 316 2283

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel +41 61 316 8540

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Lonza Group Ltd | Muenchensteinerstrasse 38 | CH-4002 Basel | Switzerland+41 61 316 81 11 | |

Record changed: 2023-06-05


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Lonza (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group BIO-Europe 2024 Stockholm BEU24 650x300px

» top